Lenvatinib mesylate: Phase III started

Eisai began the open-label, international Phase III CLEAR trial to compare 2 regimens of once-daily oral Lenvima vs. once-daily oral Sutent sunitinib in about 725 patients. Patients will receive 18 mg Lenvima plus oral Afinitor everolimus once daily; 20 mg Lenvima plus IV Keytruda pembrolizumab every 3 weeks; or Sutent for the first 4 weeks of each 6-week cycle. ...